MPT Pushes the Wall: A $2.4B Refinancing and Asset Sales Signal a Turnaround

With maturities cleared until 2028 and asset values confirmed above book, Medical Properties Trust is betting on execution over dilution.

MPT · Earnings Call · 2026-08-10

The balance sheet takes center stage

For a REIT that has seen its shares fall 55% since 2010 and trade at a fraction of its 2020 peak, the second-quarter 2026 report was more about the balance sheet than the income statement. Medical Properties Trust (MPT) delivered a comprehensive refinancing that extends $2.4 billion of debt maturities to 2032, significantly reducing near-term maturities. CEO Edward Aldag framed it plainly: “we announced a comprehensive refinancing transaction that extends $2.4 billion of debt maturities to 2032, significantly reducing near term maturities and positioning us well to pursue a balanced capital allocation strategy moving forward.” — Edward K. Aldag Jr., Chairman, President, and Chief Executive Officer · 2026-08-10 The mechanics are a two-step process. Step 1, executed immediately, involved issuing $2.4 billion in secured notes (9.25% coupon, 5.5-year term) to fully redeem the €500 million unsecured note, retire roughly 53% of the 2027 notes, and exchange another $1.2 billion of longer-dated unsecured notes at a discount. Step 2, expected in coming weeks, will repay the rest of the 2027 notes, establish a new revolver, and eliminate the 2027 term loan. The result: Step 2 leaves MPT with no debt maturities until June 2028—a runway the company has been chasing for years. CFO Steve Hamner described the impact on the sole maintenance covenant: "that will go all the way up to an actual of almost 200%, and completion of step 2, will drive it up again as much as to 300%"—providing headroom for further deleveraging.

Asset sales as proof of value

The refinancing alone would have been notable, but MPT paired it with a clear demonstration of underlying asset value. Hamner noted: “sophisticated third party investors have affirmed that market values of our hospital assets exceed their book values.” — R. Steven Hamner, Executive Vice President and Chief Financial Officer · 2026-08-10 The InfraCore IPO in Switzerland generated $140 million in proceeds at valuations above book. A transaction closing imminently will deliver about $172 million in after-debt cash proceeds, reflecting a 60% increase over original investment and a 34% IRR. Hamner added:

we are in discussions with potential buyers of additional assets that if completed, will generate hundreds of millions of dollars more in sale proceeds at pricing well above our original investments.
R. Steven Hamner, Executive Vice President and Chief Financial Officer · 2026-08-10

These asset sales are not just liquidity events—they are validation that the company's unsecured note and equity market valuations have been too pessimistic.

Operational momentum behind the balance sheet

While the capital structure story dominated, operations showed continued progress. Post-acute operators delivered the strongest growth, with EBITDARM up $70 million year over year, led by Median (+24%) and Ernest Health (+13%). HSA, a key transitioned tenant, began paying 75% of contractual rent and is expected to reach 100% in September. NOR started at 50% in June. Management reiterated the goal of over $1 billion annualized cash rent by year-end. These metrics matter because they support the deleveraging plan: asset sales can be used to pay down expensive secured debt, while rising cash rent improves coverage.

Risks remain, but the path is clearer

Despite the positive tone, MPT's balance sheet remains heavily levered. The company's liabilities-to-assets ratio stands at 69%, up from 49% a decade ago, and interest expense continues to climb. Operating cash flow was negative in the latest quarter, reflecting working capital swings. The company's own stock price has been flat over the last 90 days, indicating that sellers are waiting for execution rather than rewarding the announcement. Yet MPT is now in a position to buy time: with a cleared debt schedule, improved covenant cushion, and a pipeline of asset sales at accretive prices, the company is betting that patience will pay off. As Aldag noted in a prior call: “I think you should assume it will start immediately” — Edward Aldag, Chairman, President and Chief Executive Officer · 2025-10-30—referring to share buybacks when conditions were less favorable. Today, the focus has shifted from buybacks to balance sheet repair, a shift that could finally set up a re-rating if asset sales continue to close and rent ramps as planned.